59th American College of Cardiology Annual Scientific SessionACC.10
The American College of Cardiology (ACC) is holding its Annual Scientific Session and Innovation in Intervention. The annual meeting of the ACC is unsurpassed among clinical cardiology meetings and is one of the most highly attended and respected events in cardiovascular medicine. It is a forum for the latest and most innovative findings in cardiovascular science, as well as the most clinically relevant practical applications. For more information call (202) 375-6000 or visit www.cardiosource.org/acc.
Among the 2,300 abstracts offered to 20,000 attendees at the American College of Cardiology (ACC) meeting in Atlanta, Georgia, from March 14 to 16, 2010, results for intensive therapies for blood pressure and lipids were disappointing; however, a new factor Xa agent (betrixaban) showed promise in late-breaking clinical trials. Other sessions reviewed here showed a possible safety deficit for one contrast agent used in cardiac catheterization, benefits for some early use of clopidogrel and a glycoprotein IIb/IIIa inhibitor (eptifibatide) in acute coronary syndromes, a new formulation of an older drug (diazoxide) for hypertriglyceridemia, and a more powerful lipid-lowering combination of rosuvastatin and ezetimibe.